Gyros AB Quality Management System Receives ISO 9001:2008 Certification
News Dec 18, 2012
Gyros AB has announced that its quality management system has received ISO 9001:2008 certification.
The certification offers further reassurance to customers using the Gyros nanoliter-scale immunoassay platform that the products and services they receive are of a consistently high standard.
The Gyros platform is used by major biopharmaceutical companies and their service providers worldwide to improve productivity and efficiency during the development of biotherapeutics and vaccines, boosting time-critical workflows and helping to meet regulatory demands.
The quality management system was ISO 9001:2008 certified by Svensk Certifiering Norden.
Erik Walldén, CEO at Gyros, commented: “At Gyros we have developed our Quality Management System over many years in order to establish well-functioning operating procedures for all parts of the company. Becoming ISO 9001 registered enables customers to feel even more confident in our products and services, as this is a confirmation that we follow internationally accepted standards for quality management.”
Understanding of Platelet Production Challenged By State of the Art ImagingNews
Correlative light-electron microscopy is being used to increase our knowledge of how platelets are made in the body and the results are challenging previously held understandings.READ MORE
Miniature Testing of Drug Pairs on Tumor BiopsiesNews
Combinations of cancer drugs can be quickly and cheaply tested on tumour cells using a novel device. The research marks the latest advancement in the field of personalised medicine. Using a microfluidic device that fits in the palm of your hand, scientists screened over 1100 treatment conditions on patient tumour cells. In the future, such tests could be used to inform clinicians on safe and effective combinations of cancer treatments.READ MORE
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.